TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
26/03/2025
Voltar para busca
Dado oficial do USPTO
BICYCLE THERAPEUTICS
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
33
Atualização mais recente
02/04/2025
Classificação
Registrada
Tipo de marca
Mista
Classes Nice
5, 42, 44
Data de depósito
26/11/2021
Data de registro
03/10/2023
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
03/10/2023
Última transação
02/04/2025
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
5
Tipo de titular
99
Localização do titular
GB
Examinador
ORNDORFF, LINDA
Unidade examinadora
M20
Localização atual
PUBLICATION AND ISSUE SECTION
Descrição da marca
The mark consists of the wording BICYCLE in black with the two letters "C" stylized in gold over the word THERAPEUTICS in black.
Titulares e representantes
Titulares
Bicycletx Limited
Representantes
Christina M. Licursi Wolf, Greenfield & Sacks, P.C.
Classificação técnica
Classes Nice
Classe 5Classe 42Classe 44
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceuticalspreparations and products for use in the treatment and prevention of disease in the field of oncology for both solid and liquid tumoursfor use in the treatment and prevention of metabolic diseaseurology and renal diseasein the cardiovascular fieldin the field of hematologyfor use in the treatment and prevention of respiratorychronic and acute inflammatory disease and auto-immune disordersgastrointestinal diseasebacterial and viral infectious diseaseneurological and psychiatric disorders; pharmaceutical products and preparations for use in the treatment and prevention of disease in the field of oncology; pharmaceutical products and preparations for use in the treatment and prevetion of disease in the field of ophthalmology; pharmaceutical products and preparations for use in the treatment and prevention of disease in the field of neurology; anti-infective pharmaceutical products and preparations; pharmaceutical products and preparations for the treatment and/or prevention of respiratory disease; pharmaceutical products and preparations for the treatment and/or prevention of cardiovascular disease; pharmaceutical products and preparations for the treatment and/or prevention of metabolic disease; pharmaceutical products and preparations for the treatment and/or prevention of viral infections; pharmaceutical products and preparations for use in diagnostics and imagingclinical imaging agents; pharmaceutical products and preparations for the treatment and/or prevention of renal disease; pharmaceutical products and preparations for the treatment and/or prevention of gastrointestinal disease; pharmaceutical products and preparations for the treatment and/or prevention of muscular skeletal disease
Classe 42
Scientific and technological services and research and design relating theretoscientific researchnew product design servicesnew study design services in the fields of the development of future human and veterinary medical treatments in the field of oncology for both solid and liquid tumorsmetabolic diseaseurology and renal diseasecardiovascularhematologyrespiratorychronic and acute inflammatory disease and auto-immune disordersgastrointestinal diseasebacterial and viral infectious diseaseneurological and psychiatric disordersdiagnostic preparations and clinical imaging agents; industrial analysis and research services in the fields of oncology for both solid and liquid tumorsmetabolic diseaseurology and renal diseasecardiovascularhematologyrespiratorychronic and acute inflammatory disease and auto-immune disordersgastrointestinal diseasebacterial and viral infectious diseaseneurological and psychiatric disordersdiagnostic preparations and clinical imaging agents; pharmaceutical research and development services; medical research and development services; pharmaceutical testing and medical and scientific researchconducting clinical trials for others; medical and scientific researchconducting clinical trials for others; research and development in the field of oncology; research and development in the field of ophthalmology; research and development in the field of neurology; research and development in the field of anti-infective pharmaceuticals; research and development in the field of respiratory disease; research and development in the field of cardiovascular disease; research and development in the field of metabolic disease; research and development in the field of antiviral drugs; research and development in the field of diagnostics and imaging; research and development in the field of renal disease; research and development in the field of gastrointestinal disease; research and development in the field of muscular skeletal disease; information consultancy and advisory services relating to the aforesaid
Classe 44
Medical services; healthcare services for the treatment and prevention of disease in the field of oncology for both solid and liquid tumoursfor the treatment and prevention of metabolic diseaseurology and renal diseasecardiovascular diseasesfor the treatment and prevention of disease in the field of hematologyfor the treatment and prevention of respiratorychronic and acute inflammatory disease and auto-immune disordersgastrointestinal diseasebacterial and viral infectious diseaseneurological and psychiatric disorders; pharmaceutical compounding services; medical consulting services; advisory services relating to pharmaceuticals; medical and pharmaceutical consultation and providing information relating to diagnosticprophylactic and therapeutic properties of pharmaceuticals; medical services in the field of oncology; medical services in the field of ophthalmology; medical services in the field of neurology; medical services in the field of anti-infectives; medical services in the field of respiratory disease; medical services in the field of cardiovascular disease; medical services in the field of metabolic disease; medical services in the field of the treatment and/or prevention of viral infections; medical services in the field of diagnostics and imaging; medical services in the field of renal disease; medical services in the field of gastrointestinal disease; medical services in the field of muscular skeletal disease; pharmaceutical compounding services in the field of oncology; pharmaceutical compounding services in the field of ophthalmology; pharmaceutical compounding services in the field of neurology; pharmaceutical compounding services in the field of anti-infectives; pharmaceutical compounding services in the field of respiratory disease; pharmaceutical compounding services in the field of cardiovascular disease; pharmaceutical compounding services in connection with metabolic disease; pharmaceutical compounding services in connection with the treatment and/or prevention of viral infections; pharmaceutical compounding services in connection with diagnostics and imaging; pharmaceutical compounding services in connection with renal disease; pharmaceutical compounding services in connection with gastrointestinal disease; pharmaceutical compounding services in connection with muscular skeletal disease; informationconsultancy and advisory services relating to the aforesaid; medical testing for diagnostic or treatment purposes in the field of oncology for both solid and liquid tumoursmetabolic diseaseurology and renal diseasecardiovascular diseaseshematologyrespiratory diseasechronic and acute inflammatory disease and auto-immune disordersgastrointestinal diseasebacterial and viral infectious diseaseneurological and psychiatric disorders
Publicações
Histórico de despachos e eventos da marca no USPTO.
33 publicações encontradas
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
26/03/2025
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
26/03/2025
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
26/03/2025
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
26/03/2025
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
26/03/2025
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
30/01/2024
FICS
FINAL DISPOSITION NOTICE SENT TO IB
09/01/2024
FIMP
FINAL DISPOSITION PROCESSED
09/01/2024
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
03/01/2024
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
16/12/2023
NREP
NEW REPRESENTATIVE AT IB RECEIVED
01/12/2023
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
03/10/2023
R.PR
REGISTERED-PRINCIPAL REGISTER
03/10/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
18/07/2023
PUBO
PUBLISHED FOR OPPOSITION
18/07/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
28/06/2023
CNEA
EXAMINERS AMENDMENT MAILED
13/06/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
13/06/2023
XAEC
EXAMINER'S AMENDMENT ENTERED
13/06/2023
CNEA
EXAMINERS AMENDMENT -WRITTEN
13/06/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
12/06/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
12/06/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
12/06/2023
RFNP
REFUSAL PROCESSED BY IB
15/01/2023
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
23/12/2022
RFRR
REFUSAL PROCESSED BY MPU
22/12/2022
MAFR
APPLICATION FILING RECEIPT MAILED
11/10/2022
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
08/10/2022
CNRT
NON-FINAL ACTION WRITTEN
07/10/2022
DOCK
ASSIGNED TO EXAMINER
07/10/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
07/10/2022
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
06/10/2022
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace BICYCLE THERAPEUTICS ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.